Printer Friendly

GenoLogics becomes Illumina's preferred LIMS provider for HiSeq X Ten sequencing system.

M2 PHARMA-September 5, 2014-GenoLogics becomes Illumina's preferred LIMS provider for HiSeq X Ten sequencing system

(C)2014 M2 COMMUNICATIONS

5 September 2014 - Canada-based GenoLogics Life Sciences Software, active in developing laboratory information management systems (LIMS), said yesterday it had been picked by US genetic variation and function analysis specialist Illumina Inc (NASDAQ:ILMN) as the preferred LIMS provider to support customers of the HiSeq X Ten sequencing system.

As part of the deal, the parties are collaborating to provide support for HiSeq X Ten whole-genome workflows and analysis pipelines, including those that Illumina will utilise internally. Furthermore, the US firm will use GenoLogics' LIMS to support its partnership with Genomics England to sequence 100,000 genomes.

The accord pairs the USD-1,000 (EUR 772) genome with the LIMS, which will additionally help the sequencing community sequence human whole genomes.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 5, 2014
Words:150
Previous Article:Merck wins accelerated approval from the US FDA for KEYTRUDA for unresectable or metastatic melanoma.
Next Article:Pacific Edge gets US patent for melanoma detection technology.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters